Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in precision biomarker science, today announced that on July 15, 2026, an inducement grant (the “Inducement Grant”) was made to Jason Faessler in connection with the commencement of his employment as the Chief Financial officer and Treasurer of the Company. The Inducement Grant consisted of 141,820 restricted stock units (“RSUs”) representing 141,820 shares of Quanterix common stock.
The RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the Company or one of its subsidiaries through the vesting dates.
The Inducement Grant was granted under the Company’s Amended and Restated 2025 Inducement Plan as an inducement material to Mr. Faessler entering employment in accordance with Nasdaq Listing Rule 5635(c)(4) and was approved by the Compensation Committee of the Company’s Board of Directors.
About Quanterix
Quanterix is a global leader in precision biomarker science, making biology measurable to deliver earlier insights and support breakthroughs in disease research, diagnostics, and drug development. Its Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. Through the acquisition of Akoya Biosciences, Quanterix Spatial solutions deliver high-plex, quantitative protein analysis in tissue at single-cell resolution. Combined with Accelerator Laboratory services, Quanterix gives researchers the tools and expertise to translate discovery into precision diagnostics. Learn more at www.quanterix.com.
Media
Sarah Dolny
media@quanterix.com
Investor Relations
ir@quanterix.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260716322350/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States